Aurobindo Pharma Limited (AUROPHARMA.NS)
INR 1266.0
(1.48%)
INR 1266.0
(1.48%)
| Breakdown | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | 24.64 Billion | 23.86 Billion | 50.16 Billion | 33.28 Billion | 43.81 Billion | 16.22 Billion |
| Net Income | 31.72 Billion | 26.12 Billion | 33.72 Billion | 73.43 Billion | 37.43 Billion | 30.91 Billion |
| Depreciation & Amortization | 15.21 Billion | 12.44 Billion | 11.26 Billion | 10.55 Billion | 9.66 Billion | 6.67 Billion |
| Deferred income taxes | - | -3.39 Billion | - | -12.01 Billion | - | - |
| Stock-based compensation | 89.1 Million | -57.5 Million | - | 86.2 Million | - | - |
| Change in working capital | -16.75 Billion | -10.94 Billion | 15.57 Billion | -10.66 Billion | 2.76 Billion | -15.1 Billion |
| Other non-cash items | 34.73 Billion | -299.6 Million | -10.4 Billion | -28.1 Billion | -6.05 Billion | -6.27 Billion |
| Investing Cash Flow | -45.36 Billion | -39.77 Billion | -32.11 Billion | 5.98 Billion | -15.67 Billion | -28.76 Billion |
| Investments in PPE | -35.61 Billion | -27.2 Billion | -27.04 Billion | -18.73 Billion | -14.31 Billion | -16.05 Billion |
| Acquisitions | 602.8 Million | -915.9 Million | -6.24 Billion | 25.92 Billion | -1.68 Billion | -13.19 Billion |
| Investment purchases | -257 Million | -20.14 Billion | -8.24 Billion | -1.59 Billion | -1.87 Billion | -463.1 Million |
| Sales/Maturities of investments | 1.79 Billion | 23.51 Billion | 4.61 Billion | -3.68 Billion | 1.87 Billion | 463.1 Million |
| Other Investing Activities | -11.89 Billion | -15.03 Billion | 4.81 Billion | 4.08 Billion | 322 Million | 484.8 Million |
| Financing Cash Flow | 10.51 Billion | 18.14 Billion | -29.69 Billion | -13.64 Billion | -19.47 Billion | 19.19 Billion |
| Debt repayment | -14.61 Billion | -56.5 Million | -26.36 Billion | -11.37 Billion | -2.16 Billion | -3.93 Billion |
| Dividends payments | -2.63 Billion | -4.39 Billion | -2.63 Billion | -2.34 Billion | -1.88 Billion | -1.46 Billion |
| Common Stock Repurchased | - | - | - | - | -15.41 Billion | 24.72 Billion |
| Common Stock Issuance | - | - | - | - | 1.9 Million | 600 Thousand |
| Other Financing Activities | -3.35 Billion | 22.59 Billion | -689.1 Million | 65.1 Million | -127.9 Million | -138.6 Million |
| Accounts receivables | -2.64 Billion | -4.32 Billion | -4.1 Billion | 7.44 Billion | -6.56 Billion | -202.4 Million |
| Accounts payables | 5.82 Billion | 7.07 Billion | 1.1 Billion | 1.26 Billion | 2.95 Billion | -3.74 Billion |
| Inventory | -13.03 Billion | -9.26 Billion | 14.97 Billion | -15.93 Billion | -5.26 Billion | -8.86 Billion |
| Other working capital | -6.9 Billion | -4.43 Billion | 3.6 Billion | -3.43 Billion | 11.64 Billion | -2.29 Billion |
| Cash at beginning of period | 43.98 Billion | 41.62 Billion | 53.29 Billion | 27.46 Billion | 18.75 Billion | 12.09 Billion |
| Cash at end of period | 62.78 Billion | 43.92 Billion | 41.62 Billion | 53.29 Billion | 27.46 Billion | 18.75 Billion |
| Capital Expenditure | -35.61 Billion | -27.2 Billion | -27.04 Billion | -18.73 Billion | -14.31 Billion | -16.05 Billion |
| Effect of forex changes on cash | 141.7 Million | -600 Thousand | 2 Million | -21.2 Million | 47.8 Million | 13.8 Million |
| Net cash flow / Change in cash | 18.79 Billion | 2.29 Billion | -11.67 Billion | 25.83 Billion | 8.71 Billion | 6.65 Billion |
| Free Cash Flow | -10.96 Billion | -3.33 Billion | 23.11 Billion | 14.55 Billion | 29.5 Billion | 166.2 Million |
| Breakdown | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 | 2023 Q1 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 9.19 Billion | 9.08 Billion | 31.72 Billion | 9.36 Billion | 7.57 Billion | 5.7 Billion |
| Depreciation & Amortization | - | - | 15.21 Billion | 4.23 Billion | 7.44 Billion | 3.26 Billion |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | 89.1 Million | 89.1 Million | - | - | - |
| Change in working capital | - | - | -16.75 Billion | - | -8.57 Billion | - |
| Other non-cash items | -9.19 Billion | -9.17 Billion | 34.73 Billion | -9.36 Billion | -7.57 Billion | -5.7 Billion |
| Investing Cash Flow | - | - | -45.36 Billion | - | -30.61 Billion | - |
| Investments in PPE | - | - | -35.61 Billion | - | -14.95 Billion | - |
| Acquisitions | - | - | 602.8 Million | - | - | - |
| Investment purchases | - | - | -257 Million | - | - | - |
| Sales/Maturities of investments | - | - | 1.79 Billion | - | - | - |
| Other Investing Activities | - | - | -11.89 Billion | - | -15.65 Billion | - |
| Financing Cash Flow | - | - | 10.51 Billion | - | 12.92 Billion | - |
| Debt repayment | - | - | -14.61 Billion | - | - | - |
| Dividends payments | - | - | -2.63 Billion | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | - | - | -3.35 Billion | - | 12.92 Billion | - |
| Accounts receivables | - | - | -2.64 Billion | - | -865.5 Million | - |
| Accounts payables | - | - | 5.82 Billion | - | - | - |
| Inventory | - | - | -13.03 Billion | - | -7.71 Billion | - |
| Other working capital | - | - | -6.9 Billion | - | - | - |
| Cash at beginning of period | - | - | 43.98 Billion | 70.71 Billion | 73.34 Billion | 43.98 Billion |
| Cash at end of period | - | - | 62.78 Billion | 79.18 Billion | 41.28 Billion | 50.51 Billion |
| Capital Expenditure | - | - | -35.61 Billion | - | -14.95 Billion | - |
| Effect of forex changes on cash | - | - | 141.7 Million | - | 49.6 Million | - |
| Net cash flow / Change in cash | - | - | 18.79 Billion | 8.46 Billion | -32.06 Billion | 6.53 Billion |
| Free Cash Flow | - | - | -10.96 Billion | 8.46 Billion | 47.2 Million | 6.53 Billion |
GSTC
NCL
PCAR
IGLD-M
3648
BETRF